TNF, tumor necrosis factor, 7124

N. diseases: 2724; N. variants: 31
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE BT-11 significantly decreases interferon gamma positive (IFNγ+) and tumor necrosis factor alpha positive (TNFα+) cluster of differentiation 4 positive (CD4+) T cells and increases forkhead box P3 positive (FOXP3+) CD4+ T cells in colonic lamina propria mononuclear cells from patients with CD and patients with UC at concentrations of 0.01 µM when treated ex vivo. 31077582 2020
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE The activation of A3AR by 2-Cl-IB-MECA significantly decreased TNF-α and IL-1β production and attenuated the NF-κB p65 activation in colonic tissues from patients with UC. 31714673 2020
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Treatment with tumor necrosis factor antagonists increased steadily for patients with CD (43.4% of all patients in Brazil were treated in 2014) but less so for patients with UC (4.5% of all patients were treated in 2014).Surgery for IBD decreased with time. 31252191 2020
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor. 31628842 2020
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE To date, responsiveness to tumor necrosis factor alpha inhibitors in ulcerative colitis (UC) patients is not predictable. 31782956 2020
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE Finally, colonic IL-8+ T cells co-expressed GM-CSF, TNF- and IL-6 were detected ex vivo and, promoted by IL-12 in the mucosa and mLNs in UC only. 31206576 2020
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE Head to head comparison of two commercial fecal calprotectin kits as predictor of Mayo endoscopic sub-score and mucosal TNF expression in ulcerative colitis. 31790426 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE Compared with that in the DSS group, FMT ameliorated the severity of inflammation due to ulcerative colitis in mice, which was accompanied by a significantly decreased MPO activity, reduced levels of TNF-α and IL-1β, and an increased level of IL-10 in colon tissue (all P<0.05). 30906449 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Expression levels of IgA and sIgA decreased, while IL-6, IL-8 and TNF-α further increased in the stress-treated UC mice (P<0.05). 30783488 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE This is the first time that the effect of original CS against UC in mice has been reported and it is through promoting dominant intestinal microflora such as <i>Blautia</i>, mitigating intestinal microflora dysbiosis, and regulating the expressions of TNF-α, claudin-1, occludin, and ZO-1. 31731793 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 GeneticVariation disease BEFREE We aimed to investigate the impact of the single nucleotide polymorphisms of rs34436714 of the NOD-like receptor protein 12 gene on the production of tumor necrosis factor-alpha (TNFα) in patients with inflammatory bowel disease (IBD)In a matched case-control study 90 patients with IBD, 56 with Crohn disease (CD) and 34 with ulcerative colitis, were genotyped and compared to 98 healthy comparators matched for age and gender. 31169706 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Multiple Cytokine Profiling: A New Model to Predict Response to Tumor Necrosis Factor Antagonists in Ulcerative Colitis Patients. 30544140 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Rates of anti-TNF therapy during emergency admission for UC have increased whereas overall colectomy rates have fallen. 31714573 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE The levels of LMR, endotoxin, and TNF-α were higher in the UC group than in the CD group, but 25(OH)D was lower (p<0.05). 30429108 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Baicalin significantly increased the activity of SOD, CAT and GSH-Px in colon tissue of rats with UC, but significantly decreased the content of MDA, IL-1β, MPO, PEG2 and TNF-α in colon tissue of rats with UC. 31103874 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Aberrant activation of the immune response to resident microflora contributes to overproduction of TNF-α in the mucosal tissue of the gastrointestinal tract; a hallmark of UC. 30615542 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE The cytokine TNF is thought to play a major role in the immunopathogenesis of ulcerative colitis, and anti-TNF antibodies are considered as cornerstones of clinical therapy. 31747580 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE In patients with UC (overall or naive to TNF antagonist therapy), a significantly greater percentage of patients given vedolizumab achieved the predefined composite symptom score at weeks 2, 4, and 6 compared to those given placebo. 29857145 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Baseline whole blood TREM1 was downregulated in future anti-TNF responders, both in UC (FC = 0.53, p = .001) and CD (FC = 0.66, p = .007), as well as in the complete cohort (FC = 0.67, p < .001). 30685385 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE To examine whether there is an increased risk of developing Crohn's disease (CD) and ulcerative colitis (UC) while under treatment with anti-TNFα agents for diseases other than inflammatory bowel disease (IBD) METHODS: A nationwide cohort study, based on Danish health registries, of all patients who utilised anti-TNFα agents for non-IBD indications. 31267570 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE Two main points may help physicians to decide when the surgical option may be considered in patients with chronic refractory UC: (1) a first risk stratification can be obtained by analyzing factors at baseline and medical history, including the previous exposure to anti-TNFs; (2) during therapy with biologics, the early assessment (after 12-16 weeks of treatment) of clinical and endoscopic response is a strong predictor of the subsequent risk of colectomy. 30826279 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE The levels of IL-6 and TNF-α in peripheral blood in the UC patient group were significantly increased compared with those in the healthy adult group (P<0.01), while the levels of IL-10 and IL-4 in peripheral blood were significantly decreased compared with those in the healthy adult group (P<0.01). 30906432 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE The present study aimed to develop a tumor necrosis factor‑α (TNF‑α) B‑cell epitope/IL‑1β helper T lymphocyte epitope complex MAP vaccine for the alleviation of ulcerative colitis (UC) in mice. 31524230 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 AlteredExpression disease BEFREE It is found that the anti-UC activities are mainly focused on targeting inflammation or oxidative stress, which is associated with increasing the levels of anti-inflammatory cytokine (IL-4, IL-10, SOD), suppressing the levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8, IL-23, NF-κB, NO), reducing the activity of MPO, MDA, IFN-γ, and iNOS. 30797423 2019
CUI: C0009324
Disease: Ulcerative Colitis
Ulcerative Colitis
0.600 Biomarker disease BEFREE We collected information on 39 patients with an active steroid-refractory UC (31 with active severe UC and 36 failed by treatment with a tumor necrosis factor antagonist) who received a calcineurin inhibitor as induction therapy along with vedolizumab as maintenance therapy. 30213584 2019